Literature DB >> 10759233

Apolipoprotein E polymorphism in alagille syndrome and progressive familial intrahepatic cholestasis.

P Socha1, G Nowicka, I Jankowska, J Rujner, J Pawłowska, J Socha.   

Abstract

The aim of the study was to assess the apolipoprotein E polymorphism (apoE) in two familial cholestatic diseases-Alagille syndrome (AS) and progressive familial intrahepatic cholestasis (PFIC)-and to estimate its association with gallstone formation, cholesterol levels, and response to UDCA treatment. We investigated 16 children with AS age 8.8 +/- 5.7 years (mean +/- SD) and 18 children with PFIC age 6.3 +/- 4.6 years. The frequency of the epsilon-2 allele in AS and PFIC was higher and the frequency of the epsilon-3 allele was lower than in controls. Gallstones were diagnosed in nine children with PFIC and different apoE phenotypes. No association between phenotype and cholesterol levels or response to UDCA therapy was observed in the patients studied. In conclusion, the allele epsilon-2 is overrepresented in AS and PFIC, similar to primary biliary cirrhosis, although this does not seem to contribute to different cholesterol levels, gallstones, and response to UDCA therapy.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10759233     DOI: 10.1023/a:1005475106198

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  8 in total

1.  Progressive familial intrahepatic cholestasis (PFIC): evidence for genetic heterogeneity by exclusion of linkage to chromosome 18q21-q22.

Authors:  H Arnell; A Nemeth; G Annerén; N Dahl
Journal:  Hum Genet       Date:  1997-09       Impact factor: 4.132

2.  Expression and therapeutic response related to apolipoprotein E polymorphism in primary biliary cirrhosis.

Authors:  M Vuoristo; M Färkkilä; H Gylling; A L Karvonen; R Leino; J Lehtola; J Makinen; J Mattila; R Tilvis; T A Miettinen
Journal:  J Hepatol       Date:  1997-07       Impact factor: 25.083

3.  Mutations in the human Jagged1 gene are responsible for Alagille syndrome.

Authors:  T Oda; A G Elkahloun; B L Pike; K Okajima; I D Krantz; A Genin; D A Piccoli; P S Meltzer; N B Spinner; F S Collins; S C Chandrasekharappa
Journal:  Nat Genet       Date:  1997-07       Impact factor: 38.330

4.  Alagille syndrome is caused by mutations in human Jagged1, which encodes a ligand for Notch1.

Authors:  L Li; I D Krantz; Y Deng; A Genin; A B Banta; C C Collins; M Qi; B J Trask; W L Kuo; J Cochran; T Costa; M E Pierpont; E B Rand; D A Piccoli; L Hood; N B Spinner
Journal:  Nat Genet       Date:  1997-07       Impact factor: 38.330

5.  Apolipoprotein E polymorphism and gallstones.

Authors:  A Bertomeu; E Ros; D Zambón; M Vela; R M Pérez-Ayuso; E Targarona; M Trías; C Sanllehy; E Casals; J M Ribó
Journal:  Gastroenterology       Date:  1996-12       Impact factor: 22.682

6.  Cholesterol crystallization in human gallbladder bile: relation to gallstone number, bile composition, and apolipoprotein E4 isoform.

Authors:  K J Van Erpecum; G P Van Berge-henegouwen; E R Eckhardt; P Portincasa; B J Van De Heijning; G M Dallinga-Thie; A K Groen
Journal:  Hepatology       Date:  1998-06       Impact factor: 17.425

Review 7.  Apolipoprotein E polymorphism and atherosclerosis.

Authors:  J Davignon; R E Gregg; C F Sing
Journal:  Arteriosclerosis       Date:  1988 Jan-Feb

8.  Apolipoprotein E phenotype determined by agarose gel electrofocusing and immunoblotting.

Authors:  I F McDowell; G B Wisdom; E R Trimble
Journal:  Clin Chem       Date:  1989-10       Impact factor: 8.327

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.